Advertisement

Pharmacy World & Science

, Volume 30, Issue 6, pp 741–749 | Cite as

First renin inhibitor, aliskiren, for the treatment of hypertension

  • Darren M. Triller
  • Samuel D. Evang
  • Mina Tadrous
  • Bong Kyu YooEmail author
Review Article

Abstract

Aim of the review To systematically analyze the efficacy and safety of aliskiren for the treatment of hypertension in comparison to placebo, other monotherapy, and various combination therapies. Method A PubMed database (1966-June 2008) search was conducted with aliskiren as a search term with limits of humans, written in English, and in title only. Phase III pivotal clinical studies retrieved by PubMed database and resources such as printed labeling, approval letter, pharmacology reviews, and medical reviews posted in Drug@FDA website were evaluated with regard to study design and outcomes of efficacy and safety. Results Six Phase III pivotal clinical studies compared various doses of aliskiren to placebo and some studies compared aliskiren to treatment with other monotherapies or combinations. Aliskiren in doses of 300 mg showed a statistically significant reduction in both systolic and diastolic blood pressure versus placebo. Comparison to other antihypertensive treatments suggest that aliskiren doses of 150 and 300 mg may induce blood pressure changes similar to those seen with moderate doses of hydrochlorothiazide or angiotensin receptor blockers. Aliskiren in combination with angiotensin receptor blockers or hydrochlorothiazide showed additional blood pressure reduction only when higher doses of aliskiren were used. Aliskiren appears to be well tolerated, with diarrhea being the only statistically significant adverse event. Conclusion Aliskiren is a novel antihypertensive that exerts its effects through the direct inhibition of renin. Although the drug is well tolerated, its modest effects on blood pressure and the present lack of evidence of impact on objective cardiovascular outcomes appear to limit its utility in the general treatment of hypertension at this time.

Key words

Adverse events Aliskiren Blood pressure Efficacy Hypertension Renin inhibitor 

Notes

Acknowledgements

The authors wish to acknowledge the support of the Yeungnam University, South Korea.

Funding

This research was supported by the Yeungnam University research grant in 2007.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Approval Letter. http://www.fda.gov/cder/foi/nda/2007/021985s000_APPROV.pdf Accessed on 23 June 2008.
  2. 2.
    Pharmacology Review Part 2. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P2.pdf Accessed on 23 June 2008.
  3. 3.
    Pharmacology Review Part 3. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P3.pdf Accessed on 23 June 2008.
  4. 4.
    Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705. doi: 10.1016/S0006-291X(03)01451-7.PubMedCrossRefGoogle Scholar
  5. 5.
    Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137–43. doi: 10.1161/01.HYP.0000101688.17370.87.PubMedCrossRefGoogle Scholar
  6. 6.
    Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–33. doi: 10.1097/01.ASN.0000146686.35541.29.PubMedCrossRefGoogle Scholar
  7. 7.
    Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007;20:587–97. doi: 10.1016/j.amjhyper.2007.04.001.PubMedCrossRefGoogle Scholar
  8. 8.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1–8. doi: 10.1161/hy0102.102293.PubMedCrossRefGoogle Scholar
  9. 9.
    Kalus J. Aliskiren: a novel oral renin inhibitor for the treatment of hypertension. Formulary. 2006;41:631–8.Google Scholar
  10. 10.
    Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–63. doi: 10.1016/j.jacc.2006.11.032.PubMedCrossRefGoogle Scholar
  11. 11.
    Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–26. doi: 10.1097/HJH.0b013e3280103a6b.PubMedCrossRefGoogle Scholar
  12. 12.
    Oh BH. Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother. 2007;8:2839–49. doi: 10.1517/14656566.8.16.2839.PubMedCrossRefGoogle Scholar
  13. 13.
    Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol Rev. 2007;15:242–56. doi: 10.1097/CRD.0b013e318093e43a.PubMedCrossRefGoogle Scholar
  14. 14.
    Van Tassell BW, Munger MA. Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother. 2007;41:456–64. doi: 10.1345/aph.1H549.PubMedCrossRefGoogle Scholar
  15. 15.
    Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007;67:1767–92. doi: 10.2165/00003495-200767120-00008.PubMedCrossRefGoogle Scholar
  16. 16.
    Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med. 2007;8(Suppl 2):S22–30.PubMedGoogle Scholar
  17. 17.
    O’Brien E. Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin Investig Drugs. 2006;15:1269–77. doi: 10.1517/13543784.15.10.1269.PubMedCrossRefGoogle Scholar
  18. 18.
    Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997–1005. doi: 10.1291/hypres.29.997.PubMedCrossRefGoogle Scholar
  19. 19.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–8. doi: 10.1161/01.CIR.0000156466.02908.ED.PubMedCrossRefGoogle Scholar
  20. 20.
    Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9. doi: 10.1016/S0140-6736(07)61124-6.PubMedCrossRefGoogle Scholar
  21. 21.
    Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20. doi: 10.1016/j.amjhyper.2006.06.003.PubMedCrossRefGoogle Scholar
  22. 22.
    Label Information of Tekturna. http://www.fda.gov/cder/foi/nda/2007/021985s000_PRNTLBL.pdf Accessed on 23 June 2008.
  23. 23.
    Medical Review Part 1. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P1.pdf Accessed on 23 June 2008.
  24. 24.
    Medical Review Part 2. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P2.pdf Accessed on 23 June 2008.
  25. 25.
    Medical Review Part 3. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P3.pdf Accessed on 23 June 2008.
  26. 26.
    Pharmacology Review Part 4. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P4.pdf Accessed on 23 June 2008.
  27. 27.
    World Health Organization. Chapter 4: Quantifying selected major risks to health. In: The World Health Report 2002 (reducing risks, promoting healthy life). Geneva, Switzerland, 2002. p. 57.Google Scholar
  28. 28.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52. doi: 10.1161/01.HYP.0000107251.49515.c2.PubMedCrossRefGoogle Scholar
  29. 29.
    Efstratopoulos AD, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DE, Kontoyannis JT, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the hypertension study in general practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens. 2006;19:53–60. doi: 10.1016/j.amjhyper.2005.07.011.PubMedCrossRefGoogle Scholar
  30. 30.
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199–206. doi: 10.1001/jama.290.2.199.PubMedCrossRefGoogle Scholar
  31. 31.
    Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61:1461–8. doi: 10.1111/j.1742-1241.2007.01473.x.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Darren M. Triller
    • 1
  • Samuel D. Evang
    • 2
  • Mina Tadrous
    • 2
  • Bong Kyu Yoo
    • 3
    Email author
  1. 1.Pharmacy ServicesHealth Care Quality Improvement Program, IPROAlbanyUSA
  2. 2.Albany College of PharmacyAlbanyUSA
  3. 3.Department of Pharmacy Practice, College of PharmacyYeungnam UniversityKyungsanKorea

Personalised recommendations